Commentary| Volume 88, ISSUE 3, P337-340, September 2013

Antenatal contraception — simple, feasible, but is it safe and ethical in resource-poor environments?


      In developing countries, antenatal care is used by more women than any other reproductive health services available and many women who receive antenatal care will not receive intrapartum care by a trained provider and even fewer will receive postnatal care. At present, antenatal care provides contraceptive counselling but not contraceptive provision. An important reason for this is the perceived absence of a suitable method that could be distributed or started during antenatal care. In this article, we discuss the available options. We conclude that antenatal insertion of subdermal contraceptive implants is very likely to be safe and ethically defensible where access to contraceptive services is poor.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Contraception
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


      1. UNFPA Briefing paper. The right to contraceptive information and services for women and adolescents. UNFPA 2010 Accessed 30.7.2012.

        • Cottingham J.
        • Germain A.
        • Hunt P.
        Use of human rights to meet the unmet need for family planning.
        Lancet. 2012; 14: 172-180
        • Cates Jr., W.
        Family planning: the essential link to achieving all eight Millennium Development Goals.
        Contraception. 2010; 81: 460-461
      2. UN. Millennium Development Goals Indicator, Unmet need for family planning. Accessed 30.7.2012.

        • Speidel J.J.
        • Grossman R.A.
        Addressing global health, economic, and environmental problems through family planning.
        Obstet Gynecol. 2011; 117: 1394-1398
      3. Singh S, Darroch JE, Guttmacher Institute and UNFPA, Adding it up: cost and benefits of contraceptive services estimates 2012. Accessed 30.7.2012.

      4. McCleary-Sills J, McGonagle A, Malhotra A, Women's Demand for Reproductive Control: Understanding and Addressing Gender Barriers, Washington, DC: International Center for Research on Women, 2012 Accessed 30.7.2012.

      5. UNICEF State of the world's children 2012. Accessed 30.7.2012.

      6. World Health Organization, Postnatal care. Accessed 7.8.2012.

        • Ross J.A.
        • Winfrey W.L.
        Contraceptive use, intention to use and unmet need uring the postpartum period.
        Int Fam Plan Perspect. 2001; 27 (Accessed 6.8.2012)
      7. World Health Organization, United Nations Population Fund, UNICEF, The World Bank 2006 Pregnancy, childbirth, postpartum and newborn care, A guide for essential practice. Accessed 30.7.2012.

        • Prabhakaran S.
        • Sweet A.
        Self-administration of subcutaneous depot medroxyprogesterone acetate for contraception: feasibility and acceptability.
        Contraception. 2012; 85: 453-457
        • Short R.V.
        • Lewis P.R.
        • Renfree M.B.
        • Shaw G.
        Contraceptive effect of extended lactional amenorrhoea: beyond the Bellagio Consensus.
        Lancet. 1991; 23: 715-717
        • Ortiz A.
        • Hirol M.
        • Stanczyk F.Z.
        • Goebelsmann U.
        • Mishell D.R.
        Serum medroxyprogesterone acetate (MPA) concentrations and ovarian function following intramuscular injection of depoMPA.
        J Clin Endocrinol Metab. 1977; 44: 32-38
      8. UNICEF State of the world's children 2012. Accessed 30.7.2012.

        • Neukom J.
        • Chilambwe J.
        • Mkandawire J.
        • Mbewe R.K.
        • Hubacher D.
        Dedicated providers of long-acting reversible contraception: new approach in Zambia.
        Contraception. 2011; 83: 447-452
      9. Contraceptive Commodities for Women's Health. Accessed 28.11.2012.

        • Steiner M.J.
        • Lopez L.M.
        • Grimes D.A.
        • et al.
        Sino-implant (II)—a levonorgestrel-releasing two-rod implant: systematic review of the randomized controlled trials.
        Contraception. 2010; 81: 197-201
      10. Sivin I, Nash H, Waldman S. Jadelle® Levonorgestrel Rod Implants: A Summary of Scientific Data and Lessons Learned from Programmatic Experience. Accessed 19.10.2012.

        • Devonald B.
        Full-term pregnancy with Implanon in situ.
        J Fam Plann Reprod Health Care. 2006; 32: 268
        • Melrose E.B.
        Full-term pregnancy with Implanon in situ.
        J Fam Plann Reprod Health Care. 2006; 32: 268
        • Arunakumari P.S.
        Full-term pregnancy with Implanon in situ.
        J Fam Plann Reprod Health Care. 2006; 32: 268
        • Cooling H.
        • Pauli H.
        Full-term pregnancy with Implanon in situ.
        J Fam Plann Reprod Health Care. 2006; 32: 204
        • Sivin I.
        • Wan L.
        • Ranta S.
        • Alvarez F.
        • et al.
        Levonorgestrel concentrations during 7 years of continuous use of Jadelle contraceptive implants.
        Contraception. 2001; 64: 43-49
        • Kothare P.A.
        • Seger M.E.
        • Northrup J.
        • Mace K.
        • Mitchell M.I.
        • Linnebjerg H.
        Effect of exenatide on the pharmacokinetics of a combination oral contraceptive in healthy BMC women: an open-label, randomised, crossover trial.
        Clin Pharmacol. 2012; 12: 8
      11. NIMS USA.

      12. Davis D, Review prepared for the FDA in 2001 Teratogenic Risk of Hormonal Products for Contraception: A Review of the Literature, Accessed 30.7.2012

        • Norwitz E.R.
        • Caughey A.B.
        Progesterone supplementation and the prevention of preterm birth.
        Rev Obstet Gynecol. 2011; 4: 60-72
        • Odom L.N.
        • Taylor H.S.
        Environmental induction of the fetal epigenome.
        Expert Rev Obstet Gynecol. 2010; 5: 657-664
        • Cleland J.
        • Conde-Agudelo A.
        • Peterson H.
        • Ross J.
        • Tsui A.
        Contraception and health.
        Lancet. 2012; 380: 149-156
        • Beauchamp T.L.
        • Childress J.F.
        Principles of Biomedical Ethics. 6th ed. Oxford University Press, New York, NY2009
        • United Nations
        World contraceptive use, 2009 (wall chart). United Nations Population Division, New York2009